[1]
Joyce, A.M. Knowledge, Attitude and Practices regarding Tuberculosis among people diagnosed with tuberculosis and their immediate household contacts in an urban health care centre in vellore. Christian Medical College, Vellore: Tamil Nadu 2020.
[3]
Falodun, O.I.; Cadmus, I.S.; Fagade, O.E. Patterns of drug re-sistance in mycobacterium tuberculosis from tuberculosis pa-tients in ibadan nigeria. MicroMedicine., 2020, 9(1), 8-17.
[4]
Udwadia, Z.; Vendoti, D. Totally drug-resistant tuberculosis (TDR-TB) in India: Every dark cloud has a silver lining; BMJ Publishing Group Ltd, 2013.
[24]
Sia, J.K.; Georgieva, M.; Rengarajan, J. Innate immune defenses in human tuberculosis: An overview of the interactions be-tween mycobacterium tuberculosis and innate immune cells. J. Immunol. Res., 2015, 2015, 747543.
[27]
Mir, M.A.; Albaradie, R.S.; Agrewala, J.N. Innate-effector immune response elicitation against tuberculosis through An-ti-B7-1 (CD80) and Anti-B7-2 (CD86) signaling in macro-phages. IJBPAS, 2013, 2(5), 1024-1043.
[37]
Macrophages in tuberculosis: Friend or foe. Seminars in immunopathology; Springer, 2013.
[38]
van Crevel, R.; Ottenhoff, T.H.; van der Meer, J.W. Innate immunity to mycobacterium tuberculosis. Tropical diseas-es; Springer, 2003, pp. 241-247.
[44]
Abebe, M.; Kim, L.; Rook, G.; Aseffa, A.; Wassie, L.; Zewdie, M. Modulation of cell death by M. tuberculosis as a strategy for pathogen survival. Clini. Develop Immunol., 2011, 2011, 678570.
[48]
Mir, M.A. Agrewala, JN Influence of CD80 and CD86 Co-Stimulation in the modulation of the activation of antigen pre-senting cells. Current Immunology Reviews, 2007, 3(3), 160-169.
[50]
Swanson, B.I.; Mukundan, H.; Sakamuri, R.M. Discovery, de-tection and use of biomarkers; Google Patents, 2017.
[84]
Zwane, H. Investigation of the role of the TRK potassium transporter of mycobacterium tuberculosis in intra cellular sur-vival; University of Pretoria, 2012.
[85]
Elayati, K.M.M. Inflammatory dendritic cells in the host im-mune response to mycobacteria The Role of Cellular Metabo-lism; Trinity College, 2020.
[95]
Dooley, S.W.; Jarvis, W.R.; Marione, W.J.; Snider, D.E. Jr Multidrug-resistant tuberculosis; American College of Physi-cians, 1992.
[100]
Manson, A.L.; Cohen, K.A.; Abeel, T.; Desjardins, C.A.; Armstrong, D.T.; Barry, C.E., III; Brand, J.; Chapman, S.B.; Cho, S.N.; Gabrielian, A.; Gomez, J.; Jodals, A.M.; Joloba, M.; Jureen, P.; Lee, J.S.; Malinga, L.; Maiga, M.; Nordenberg, D.; Noroc, E.; Romancenco, E.; Salazar, A.; Ssengooba, W.; Ve-layati, A.A.; Winglee, K.; Zalutskaya, A.; Via, L.E.; Cassell, G.H.; Dorman, S.E.; Ellner, J.; Farnia, P.; Galagan, J.E.; Rosenthal, A.; Crudu, V.; Homorodean, D.; Hsueh, P.R.; Na-rayanan, S.; Pym, A.S.; Skrahina, A.; Swaminathan, S.; Van der Walt, M.; Alland, D.; Bishai, W.R.; Cohen, T.; Hoffner, S.; Birren, B.W.; Earl, A.M. Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance.
Nat. Genet., 2017,
49(3), 395-402.
[
http://dx.doi.org/10.1038/ng.3767] [PMID:
28092681]
[101]
Chen, S.; Teng, T.; Wen, S.; Zhang, T.; Huang, H. The aceE in-volves in mycolic acid synthesis and biofilm formation in my-cobacterium smematis. BMC Microbiol., 2020, 2020, 259.
[108]
van der Werf, M.J.; Langendam, M.W.; Huitric, E.; Manissero, D. Multidrug resistance after inappropriate tuberculosis treat-ment: A meta-analysis. Eur Respiratory Soc, 2012, 39(6), 1511-1519.
[111]
Bojang, A. Towards identifying intracellular drug targets of mycobacterium tuberculosis against hit compounds in defined growth media; University of British Columbia, 2020.
[126]
Organization, W.H. WHO best-practice statement on the off-label use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis; World Health Organization, 2017.
[127]
Organization, WH The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: Interim policy guidance. 2016.
[134]
Organization, WH WHO consolidated guidelines on tuberculosis: Module 4: Treatment: Drug-resistant tuberculosis treatment: Online annexes. 2020.
[141]
Longmore, M.; Wilkinson, I.; Baldwin, A.; Wallin, E. Oxford handbook of clinical medicine-mini editionOUP Oxford; , 2014.
[142]
Alliance, T. FDA approves new treatment for highly drug-resistant forms of tuberculosis; New York, 2019.
[151]
Gobedo, A.; Hwoldi, A.; Toma, A. Recent advances in the de-velopment of anti-tuberculosis drugs acting on multidrug-resistant strains: A review. Int. J. Pharm. Biol. Sci., 2015, 2, 1-18.
[165]
Sommer, R.C. Innovative tools and in vivo methods for tuber-culosis drug discovery and development; EPFL, 2019.